Literature DB >> 24434206

From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma.

Jonathan D Licht1, Jake Shortt2, Ricky Johnstone2.   

Abstract

Thalidomide and related drugs are key drugs for the treatment of multiple myeloma (MM). These agents bind to cereblon, a component of a ubiquitin ligase complex, altering the specificity of the complex to induce the ubiquitylation and degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors essential for MM growth.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Year:  2014        PMID： 24434206      PMCID： PMC3984916          DOI： 10.1016/j.ccr.2013.12.019

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  11 in total

1.  Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer.

Authors:  Shancheng Ren; Chuanliang Xu; Zilian Cui; Yongwei Yu; Weidong Xu; Fubo Wang; Ji Lu; Min Wei; Xin Lu; Xu Gao; You Liang; Jian-Hua Mao; Yinghao Sun
Journal:  J Mol Med (Berl)       Date:  2012-03-16       Impact factor: 4.599

2.  Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

Authors:  F E Davies; N Raje; T Hideshima; S Lentzsch; G Young; Y T Tai; B Lin; K Podar; D Gupta; D Chauhan; S P Treon; P G Richardson; R L Schlossman; G J Morgan; G W Muller; D I Stirling; K C Anderson
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

3.  Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

Authors:  Yuan Xiao Zhu; Esteban Braggio; Chang-Xin Shi; Laura A Bruins; Jessica E Schmidt; Scott Van Wier; Xiu-Bao Chang; Chad C Bjorklund; Rafael Fonseca; P Leif Bergsagel; Robert Z Orlowski; A Keith Stewart
Journal:  Blood       Date:  2011-08-22       Impact factor: 22.113

4.  Antitumor activity of thalidomide in refractory multiple myeloma.

Authors:  S Singhal; J Mehta; R Desikan; D Ayers; P Roberson; P Eddlemon; N Munshi; E Anaissie; C Wilson; M Dhodapkar; J Zeddis; B Barlogie
Journal:  N Engl J Med       Date:  1999-11-18       Impact factor: 91.245

5.  Identification of a primary target of thalidomide teratogenicity.

Authors:  Takumi Ito; Hideki Ando; Takayuki Suzuki; Toshihiko Ogura; Kentaro Hotta; Yoshimasa Imamura; Yuki Yamaguchi; Hiroshi Handa
Journal:  Science       Date:  2010-03-12       Impact factor: 47.728

6.  Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

Authors:  T Hideshima; D Chauhan; Y Shima; N Raje; F E Davies; Y T Tai; S P Treon; B Lin; R L Schlossman; P Richardson; G Muller; D I Stirling; K C Anderson
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

7.  Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.

Authors:  Jan Krönke; Namrata D Udeshi; Anupama Narla; Peter Grauman; Slater N Hurst; Marie McConkey; Tanya Svinkina; Dirk Heckl; Eamon Comer; Xiaoyu Li; Christie Ciarlo; Emily Hartman; Nikhil Munshi; Monica Schenone; Stuart L Schreiber; Steven A Carr; Benjamin L Ebert
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

8.  Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.

Authors:  A Lopez-Girona; D Mendy; T Ito; K Miller; A K Gandhi; J Kang; S Karasawa; G Carmel; P Jackson; M Abbasian; A Mahmoudi; B Cathers; E Rychak; S Gaidarova; R Chen; P H Schafer; H Handa; T O Daniel; J F Evans; R Chopra
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

9.  The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.

Authors:  Gang Lu; Richard E Middleton; Huahang Sun; MarkVic Naniong; Christopher J Ott; Constantine S Mitsiades; Kwok-Kin Wong; James E Bradner; William G Kaelin
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

10.  Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).

Authors:  Anita K Gandhi; Jian Kang; Courtney G Havens; Thomas Conklin; Yuhong Ning; Lei Wu; Takumi Ito; Hideki Ando; Michelle F Waldman; Anjan Thakurta; Anke Klippel; Hiroshi Handa; Thomas O Daniel; Peter H Schafer; Rajesh Chopra
Journal:  Br J Haematol       Date:  2013-12-13       Impact factor: 6.998
View more
  13 in total

Review 1.  Phenotypic screening in cancer drug discovery - past, present and future.

Authors:  John G Moffat; Joachim Rudolph; David Bailey
Journal:  Nat Rev Drug Discov       Date:  2014-07-18       Impact factor: 84.694

2.  LINC01234 promotes multiple myeloma progression by regulating miR-124-3p/GRB2 axis.

Authors:  Xueyan Chen; Yin Liu; Zihua Yang; Jiang Zhang; Shaoqian Chen; Jing Cheng
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

Review 3.  Immune Modulation in Hematologic Malignancies.

Authors:  Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

4.  Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.

Authors:  Philip P Chamberlain; Antonia Lopez-Girona; Karen Miller; Gilles Carmel; Barbra Pagarigan; Barbara Chie-Leon; Emily Rychak; Laura G Corral; Yan J Ren; Maria Wang; Mariko Riley; Silvia L Delker; Takumi Ito; Hideki Ando; Tomoyuki Mori; Yoshinori Hirano; Hiroshi Handa; Toshio Hakoshima; Thomas O Daniel; Brian E Cathers
Journal:  Nat Struct Mol Biol       Date:  2014-08-10       Impact factor: 15.369

5.  In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.

Authors:  E M Ocio; D Fernández-Lázaro; L San-Segundo; L López-Corral; L A Corchete; N C Gutiérrez; M Garayoa; T Paíno; A García-Gómez; M Delgado; J C Montero; E Díaz-Rodríguez; M V Mateos; A Pandiella; S Couto; M Wang; C C Bjorklund; J F San-Miguel
Journal:  Leukemia       Date:  2014-08-08       Impact factor: 11.528

6.  Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma.

Authors:  Matteo Costacurta; Stephin J Vervoort; Simon J Hogg; Benjamin P Martin; Ricky W Johnstone; Jake Shortt
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

7.  Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.

Authors:  C C Bjorklund; L Lu; J Kang; P R Hagner; C G Havens; M Amatangelo; M Wang; Y Ren; S Couto; M Breider; Y Ning; A K Gandhi; T O Daniel; R Chopra; A Klippel; A G Thakurta
Journal:  Blood Cancer J       Date:  2015-10-02       Impact factor: 11.037

8.  Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma.

Authors:  Mridul Roy; Long Liang; Xiaojuan Xiao; Yuanliang Peng; Yuhao Luo; Weihua Zhou; Ji Zhang; Lugui Qiu; Shuaishuai Zhang; Feng Liu; Mao Ye; Wen Zhou; Jing Liu
Journal:  Theranostics       Date:  2016-09-24       Impact factor: 11.556

Review 9.  Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway.

Authors:  Ian Collins; Hannah Wang; John J Caldwell; Raj Chopra
Journal:  Biochem J       Date:  2017-03-15       Impact factor: 3.857

10.  Life situation of women impaired by Thalidomide embryopathy in North Rhine-Westphalia - a comparative analysis of a recent cross-sectional study with earlier data.

Authors:  Christina Samel; Christian Albus; Irmgard Nippert; Alexander Niecke; Markus Lüngen; Holger Pfaff; Klaus M Peters
Journal:  BMC Womens Health       Date:  2019-04-03       Impact factor: 2.809
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.